Zhejiang Cancer Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.zchospital.com

Clinical Trials

Exploratory Study on the S-1 + Paclitaxel Chemotherapy for Unresectable Gastric Cancer

Phase 2

Conditions: Surgically-Created Resection Cavity
Drug Safety

Interventions: Drug: S-1 + Paclitaxel Chemotherapy

First Posted Date: 2012-12-25

Last Posted Date: 2012-12-25

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 60

Registration Number: NCT01756183

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC

Phase 1

Completed

Conditions: Stage III Non-small-Cell Lung Cancer

Interventions: Drug: Recombinant human endostatin
Drug: Etoposide (50mg/m2) IV (in the vein) on day 1 to day 5 of a 28-day cycle for 2 cycles
Drug: cisplatinum (50mg/m2) IV (in the vein) on day 1 and day 8 of a 28-day cycle for 2 cycles
Other: laboratory biomarker analysis
Other: CT perfusion imaging

First Posted Date: 2012-11-27

Last Posted Date: 2017-07-14

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 73

Registration Number: NCT01733589

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

A Prospective Randomized Study Comparing the Target Volume for Limited-stage Small Cell Lung Cancer

Phase 2

Conditions: Carcinoma of Lung
Small Cell
Limited Stage

Interventions: Radiation: hyperfractionated radiation therapy for both arms

First Posted Date: 2012-11-21

Last Posted Date: 2013-01-23

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 500

Registration Number: NCT01731548

Locations: 🇨🇳
Sun Yat-Sen University, Cancer Center, Guangzhou, Guangdong, China

Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma

Phase 2

Conditions: Esophageal Squamous Cell Carcinoma Resectable

Interventions: Drug: Nimotuzumab combined with paclitaxel and cisplatin

First Posted Date: 2012-09-20

Last Posted Date: 2012-09-20

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 60

Registration Number: NCT01688700

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Phase II Trial of Double Dose of Icotinib in Treating Brain Metastases From Non-small Cell Lung Cancer

Phase 2

Conditions: Brain Metastases
Non-small Cell Lung Cancer

Interventions: Drug: Icotinib

First Posted Date: 2012-09-20

Last Posted Date: 2012-09-20

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 20

Registration Number: NCT01688713

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Study of Relationship Between UGT1A1 Gene Polymorphism and Toxicity and Efficacy of Irinotecan in Small Cell Lung Cancer

Phase 2

Conditions: Small Cell Carcinoma of Lung

Interventions: Drug: Irinotecan

First Posted Date: 2012-07-09

Last Posted Date: 2012-07-09

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 50

Registration Number: NCT01635400

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Endostar Combination With Chemotherapy for the Metastatic Nasopharyngeal Carcinoma

Phase 2

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: endostatin

First Posted Date: 2012-06-05

Last Posted Date: 2014-02-19

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 30

Registration Number: NCT01612286

Locations: 🇨🇳
Zhejiang cancer hospital, Hangzhou, Zhejiang, China

Peri-operative Chemotherapy With ECX or XP in the Treatment of Advanced Gastric Cancer

Phase 2

Conditions: Gastric Cancer

Interventions: Drug: Peri-operative chemotherapy of ECX
Drug: Peri-operative chemotherapy of XP

First Posted Date: 2012-03-20

Last Posted Date: 2012-03-20

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 2

Registration Number: NCT01558947

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Efficacy Study of Neoadjuvant Chemotherapy With Chemoradiation Therapy for Nasopharyngeal Carcinoma

Phase 3

Conditions: Chemoradiation
Nasopharyngeal Carcinoma

Interventions: Drug: PF (cisplatin and 5-fluorouracil) group
Drug: TPF (docetaxel plus cisplatin and 5-fluorouracil) group

First Posted Date: 2012-02-20

Last Posted Date: 2013-03-05

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 400

Registration Number: NCT01536223

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Icotinib Combined With Whole Brain Radiotherapy in Treating Multiple Brain Metastases From Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer
Metastatic Cancer

Interventions: Drug: Icotinib

First Posted Date: 2012-01-23

Last Posted Date: 2014-07-23

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 20

Registration Number: NCT01514877

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy